The Karnataka High Court recently refused to quash criminal proceedings initiated against a pharmaceutical company accused of manufacturing and marketing substandard Calcium and Vitamin D3 tablets [Lifevision Healthcare & other v. State of Karnataka].
Justice Rajesh Rai K observed that the sale of substandard medicines has a direct impact on public health, and that allegations about the same cannot be brushed aside lightly.
“The allegations, if established, have a direct bearing on public health and cannot be lightly brushed aside at this stage,” the Court observed in its November 2 order.
It, therefore, dismissed a plea filed by M/s Life Vision Healthcare and its managing partner, Naveen Kumar Bansal (petitioners), seeking the quashing of the criminal case filed against them.
The case concerned 'Impcal Tablets' (Calcium Orotate with Vitamin D3 Tablets IP), manufactured by the company in September 2019. The drug, bearing batch number LTA-2497, was declared 'Not of Standard Quality' following chemical analysis, specifically with regard to the analysis for Vitamin D3.
The authorities informed the petitioners about the adverse test report on August 28, 2020. They sought a re-analysis. However, the re-analysis request was made only on April 15, 2021, by which time the drug's shelf life had expired (in February 2021).
The accused eventually moved a plea before the High Court to quash the criminal case.
They contended that the sample had been forwarded for chemical analysis two days after its seizure, contrary to Section 23(4)(i) of the Drugs and Cosmetics Act, 1940. They also argued that the delay had prejudiced their statutory right to seek a re-analysis by the Central Drugs Laboratory.
Rejecting the argument, the Court noted that the sample was seized on February 18, 2020, and forwarded for analysis on February 20, 2020. It held that the expression 'forthwith' did not require immediate forwarding without completing the other procedural steps prescribed under the Act.
“Forwarding the seized drug sample for chemical analysis within two days cannot, in the facts and circumstances of the present case, be construed as an undue or unexplained delay,” the Court concluded.
The Court also rejected the pharma company managing partner's contention that he could not be prosecuted merely on account of his designation. The Court reasoned that the complaint prima facie indicated his active involvement in the company's day-to-day affairs.
Holding that the allegations warranted a full-fledged trial, the Court dismissed the petition.
Advocates Nitin Bashir and Uday Urs appeared for the petitioners.
High Court Government Pleader Mahesha P appeared for the State.
[Read Judgment]